Perrigo Company announced that it has agreed to settle its Hatch-Waxman litigation relating to Minoxidil foam brought by Stiefel Research Australia Pty. Ltd., a GSK company. Under the terms of the settlement, Perrigo can launch in the US, a generic version of Men’s Rogaine Foam on March 1, 2012, or earlier under certain circumstances.

Rogaine (Minoxidil) Foam is used to regrow hair on the top of the scalp, and has annual sales of approximately $60 million, as measured by Information Resources, Inc.

Perrigo’s chairman and CEO Joseph C. Papa concluded, “This is another example of Perrigo’s commitment to bring products to market. Perrigo continues its focus on bringing quality, affordable healthcare to consumers.”

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products. The company is the world’s largest store brand manufacturer of OTC pharmaceutical products and infant formulas.